Rapidly progressive puberty is a distinct clinical problem from classic precocious puberty. Affected girls begin puberty at a roughly normal age, but then accelerate through the Tanner stages at an alarming pace, with bone age racing ahead of chronological age. Because estrogen drives the fusion of the growth plates, this acceleration locks in a compromised predicted adult height. Gonadotropin-releasing hormone agonists, or GnRHa, are the standard tool for halting central precocious puberty, and Chinese consensus guidelines now allow their use in rapidly progressive puberty when the height prognosis is severely threatened. Yet clinicians have noticed that some girls on GnRHa monotherapy continue to show bone age advancement, hinting that their estrogen supply does not come from the ovaries alone.

That observation points to aromatase, the CYP19A1 enzyme that converts adrenal-derived androgen precursors into estrogens in peripheral tissues. Block this enzyme with a drug like letrozole, the reasoning goes, and you shut down the second estrogen source, slowing growth plate fusion further. Third-generation aromatase inhibitors such as letrozole and anastrozole are already used for short stature, mainly in boys, where they can raise predicted adult height. In girls, however, their use has been rare—largely confined to McCune-Albright syndrome—because of a central concern: if aromatase is blocked while androgens keep flowing, androgens might accumulate and trigger virilizing effects such as hirsutism and acne.

The new study, led by researchers at the Second Hospital of Hebei Medical University in Shijiazhuang, was designed to test that concern with unprecedented hormonal resolution. The team enrolled 28 girls with advanced bone age between July 2025 and April 2026. Thirteen girls, designated Group A, started combination therapy—GnRHa injections every four weeks plus daily oral letrozole at 1.25 milligrams—from the outset. The other fifteen, Group B, were already on GnRHa monotherapy and were offered letrozole as an add-on. Group assignment reflected the timing of letrozole introduction in routine clinical care rather than systematic allocation, and the authors acknowledge this was not a randomized design.

The methodological centerpiece was liquid chromatography–tandem mass spectrometry, or LC-MS/MS, a technique that detects and quantifies steroid hormones with far greater sensitivity and specificity than traditional immunoassays. Blood samples drawn at baseline, one month, and six months were profiled across three androgen-producing routes: the classical pathway, running from DHEA through androstenedione to testosterone and dihydrotestosterone; the 11-oxygenated pathway, producing adrenal androgens such as 11-ketotestosterone; and the little-known backdoor pathway, which bypasses testosterone to generate potent dihydrotestosterone metabolites like 5α-dihydroprogesterone and 3α-androstanediol. Progestogens, estrogens, and reproductive hormones including anti-Müllerian hormone, inhibin B, and sex hormone-binding globulin rounded out the panel.

The results tell a nuanced story about which hormones respond to which part of the dual blockade. In Group A, where both drugs acted from the start, classical androgens—testosterone, androstenedione, and their metabolites—fell sharply by one month and stayed low through six months, alongside marked drops in key progestogens and both estrone and estradiol. The free androgen index, a marker of bioavailable androgen, declined progressively. Crucially, the 11-oxygenated androgens, which are largely adrenal in origin, remained essentially stable, with only a modest and transient dip in 11-ketotestosterone at one month. That pattern, the authors argue, indicates that GnRHa effectively suppresses gonadal androgen output while adrenal steroidogenesis is left untouched.

Group B offered a natural comparison: in girls whose hypothalamic-pituitary-gonadal axis was already suppressed, adding letrozole produced far fewer hormonal ripples. Estradiol and estrone fell significantly, as did AMH and inhibin B—markers of ovarian follicular activity—but most androgens and progestogens held steady. A modest rise in two upstream precursors, pregnenolone and 17-hydroxydihydroprogesterone, appeared without any corresponding increase in downstream androgens, possibly reflecting mild accumulation of substrates blocked from aromatizing. Across both groups, no girl developed clinical or biochemical hyperandrogenism: none showed hirsutism by the modified Ferriman-Gallwey score, and none developed moderate-to-severe acne.

The safety signal extended beyond androgens. No letrozole-related adverse events—liver dysfunction, rash, or gastrointestinal symptoms—were recorded during the six-month window. Bone age, assessed by hand-wrist radiographs, advanced by a mean of 0.30 years in Group A and 0.23 years in Group B over six months, both slower than the expected 0.5-year chronological progression. That slowing is exactly what dual estrogen suppression should produce at the growth plate, though the authors caution that whether it ultimately translates into taller adults can only be answered with longer follow-up. The AMH and inhibin B declines mirror findings from standard GnRHa therapy and are considered reversible after treatment stops.

The findings build on, and extend, earlier work. The Greek GAIL study showed in 2016 that anastrozole combined with leuprorelin improved predicted adult height in early-maturing girls without testosterone abnormalities or bone density problems, but it did not perform comprehensive steroid profiling. Data from postmenopausal women on letrozole, whose estrogen physiology resembles that of GnRHa-suppressed girls, show estradiol reductions of 75 to 95 percent with minimal effects on adrenal steroids—and androgen-related side effects have been reported only with the steroidal inhibitor exemestane, not with letrozole or anastrozole. In boys, letrozole monotherapy is known to cause testosterone surges through gonadotropin rebound, but the new data confirm that GnRHa counteracts that mechanism when the two are combined in girls.

The study’s authors and outside observers alike stress the limits of the evidence. With 13 and 15 participants per group, a single center, no control arm, non-randomized group assignment, and only six months of observation, the results are preliminary rather than practice-changing. Gonadotropin levels were not measured in parallel, leaving some ambiguity about hypothalamic-pituitary dynamics, and inter-laboratory variability in LC-MS/MS assays complicates comparisons across studies. Because both drugs suppress estrogen signaling, the authors call for long-term monitoring of bone mineral density and growth. Still, within those boundaries, the study delivers what the field has lacked: a steroid-wide map showing that combined GnRHa and letrozole suppresses gonadal estrogens and androgens, spares the adrenal axis, and—at least over six months—does not push girls into androgen excess. Larger, longer trials will now be needed to determine whether this dual blockade can reliably bank centimeters of adult height without trading away long-term endocrine health.

Subject of Research: Endocrine effects of combined GnRHa and letrozole therapy on serum steroid profiles in girls with advanced bone age

Article Title: Effects of combined GnRHa and letrozole on serum steroid profiles in girls with advanced bone age

Article References: Zhang, X., Zhang, Y., Xing, Y., Yang, W., Qin, Y., Gao, X., Kong, X., Cai, S., Xue, G., Fan, X., Chen, M., Liu, Y., Chen, B., Yan, X., & Zhang, H. (2026). Effects of combined GnRHa and letrozole on serum steroid profiles in girls with advanced bone age. Frontiers in Endocrinology, 17, Article 1984633. https://doi.org/10.3389/fendo.2026.1984633

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1984633

Keywords: puberty, advanced bone age, GnRHa, letrozole, aromatase inhibitor, steroid hormones, LC-MS/MS, hyperandrogenism, rapidly progressive puberty, pediatric endocrinology, predicted adult height, bone age

The research team, led by Elnaz Harooni and colleagues at Ahvaz Jundishapur University of Medical Sciences in Iran, focused on a well-established experimental approach: the letrozole-induced PCOS mouse. Letrozole is a nonsteroidal inhibitor of aromatase, the enzyme encoded by the Cyp19a1 gene that converts testosterone into estrogen. By blocking estrogen production, letrozole causes androgens to accumulate in female rodents, producing a cluster of symptoms that closely mirrors human PCOS, including androgen excess, elevated blood glucose, abnormal follicle development, and oxidative stress. The researchers administered letrozole orally at 6 milligrams per kilogram of body weight for 21 consecutive days to adult female NMRI mice, then confirmed the PCOS phenotype through daily vaginal smear cytology, which revealed disrupted and arrested estrous cycles in the treated animals.

Lauric acid is a medium-chain fatty acid that accounts for roughly 45 to 53 percent of coconut oil and is widely credited with many of the oil’s reported health benefits, from improved cognitive function in Alzheimer’s disease to reduced cardiovascular risk. Previous work has shown that lauric acid can lower body weight, improve lipid profiles, and enhance insulin sensitivity, effects that have been linked to activation of the Sirt1/AMPK signaling pathway in the liver. That pathway is central to cellular energy sensing: AMP-activated protein kinase, or AMPK, monitors intracellular energy status and maintains energy homeostasis at both the cellular and whole-body levels, while sirtuin 1, or Sirt1, is an NAD-dependent histone deacetylase involved in glucose and lipid metabolism, oxidative stress regulation, and reproductive function. Notably, Sirt1 expression in the ovary is reduced in both human PCOS patients and animal models, making the Sirt1/AMPK axis an attractive therapeutic target.

In the new experiment, forty mice were divided into four groups of ten: a normal control group, a group receiving lauric acid alone, a PCOS group receiving letrozole followed by vehicle, and a PCOS group treated with lauric acid at 150 milligrams per kilogram per day for 15 days after PCOS induction. The dose was selected on the basis of prior studies demonstrating its efficacy and safety across a wide range. The results were striking in several domains. Lauric acid treatment significantly lowered fasting blood glucose and fasting insulin concentrations in the PCOS mice, and it significantly improved both the HOMA-IR index, a standard measure of insulin resistance, and the QUICKI index, which reflects insulin sensitivity. Given that compensatory hyperinsulinemia drives many PCOS features and increases the risk of cardiovascular disease and type 2 diabetes, this metabolic improvement is clinically meaningful.

The fatty acid also reshaped the hormonal landscape of the treated animals. Letrozole had produced the classic PCOS hormonal signature: elevated luteinizing hormone, an increased LH-to-FSH ratio, and raised testosterone, accompanied by reduced follicle-stimulating hormone, progesterone, and estradiol. Fifteen days of lauric acid administration significantly decreased testosterone, LH, and the LH/FSH ratio while significantly raising estradiol levels. Mechanistically, this appears to involve restoration of the aromatase machinery: lauric acid significantly reversed the letrozole-driven decline in ovarian Cyp19a1 protein expression, the very enzyme the drug inhibits, while simultaneously reducing the elevated expression of ovarian androgen receptors that had heightened the animals’ sensitivity to accumulated androgens. Progesterone levels, however, remained depressed despite treatment, a limitation the authors openly acknowledge.

Lipid metabolism responded robustly as well. PCOS mice showed markedly elevated triglycerides and LDL cholesterol alongside reduced HDL cholesterol, a dyslipidemic pattern that mirrors the cardiovascular risk profile of human patients. Lauric acid treatment significantly increased HDL cholesterol and reduced both LDL cholesterol and triglycerides, and it significantly lowered the atherogenic index, a logarithmic marker of cardiometabolic risk calculated from the triglyceride-to-HDL ratio. Interestingly, lauric acid improved this index even in healthy mice, suggesting the fatty acid may beneficially modulate lipid handling independent of disease state. Consistent with these findings, the expression of two key adipose tissue regulators, adiponectin and peroxisome proliferator-activated receptor gamma, or PPARγ, was sharply reduced in the white adipose tissue of PCOS mice and significantly restored by lauric acid treatment. These molecules cooperate in regulating glucose and lipid homeostasis, and their upregulation may partially explain the observed improvements in insulin sensitivity.

The study also probed the oxidative and structural consequences of the disease. Ovaries from PCOS mice contained significantly higher concentrations of malondialdehyde, a lipid peroxidation product, and significantly lower total antioxidant capacity, reflecting the oxidant-antioxidant imbalance known to impair oocyte maturation, ovulation, and fertilization. Lauric acid treatment shifted both markers back toward normal. Histological examination told a parallel story: letrozole produced large ovarian cysts and drastically reduced the number of healthy and antral follicles, whereas lauric acid-treated mice showed fewer cystic follicles and a significant recovery of antral follicle formation, indicating a partial resumption of follicular development. Western blot analysis provided the molecular capstone, revealing that lauric acid significantly restored the letrozole-suppressed expression of Sirt1 and AMPK proteins within ovarian tissue.

The authors propose that these molecular changes form a coherent mechanism. Sirt1 is known to regulate aromatase expression in granulosa cells and to protect both pancreatic beta cells and ovarian granulosa cells through antioxidant and anti-inflammatory actions, while the Sirt1/AMPK pathway has been directly implicated in the insulin resistance of PCOS. The restoration of GLP-1, a gut-derived incretin hormone that fell significantly in PCOS mice and rebounded with lauric acid treatment, adds another layer, since GLP-1 receptor agonists are increasingly used to manage PCOS and have been linked to enhanced adiponectin and PPARγ activity. Not every parameter responded, however. Body weight gain induced by letrozole was not reversed, spexin, another metabolic hormone, remained unchanged, and the improvement in estrous cyclicity, though notable, with 60 percent of treated mice showing normal cycles versus 30 percent of untreated PCOS mice, did not reach statistical significance.

As the authors emphasize, this is the first study to evaluate lauric acid in a letrozole-induced PCOS model, and the findings should be interpreted as preliminary. The work was conducted in mice over a short treatment window, and the improvements, while broad, were partial and inconsistent across all measured endpoints. Translating a 150 milligram per kilogram daily dose into a safe and effective human regimen would require extensive dose-ranging, pharmacokinetic, and safety studies, and the relationship between dietary coconut oil consumption and purified lauric acid supplementation is far from straightforward. Nevertheless, the convergence of evidence, improved insulin sensitivity, corrected dyslipidemia, partially restored sex hormones, reduced oxidative stress, healthier ovarian histology, and reactivated Sirt1/AMPK signaling, positions lauric acid as a compelling candidate for further investigation as a complementary agent against the metabolic and endocrine disturbances of PCOS. Larger and longer studies will be needed to confirm whether this humble coconut-derived fatty acid can truly deliver on that promise.

Subject of Research: Effects of lauric acid on endocrine and metabolic alterations in a letrozole-induced mouse model of polycystic ovary syndrome

Article Title: Lauric acid ameliorates endocrine-metabolic alterations in letrozole-induced polycystic ovary syndrome in female mice

Article References: Harooni, E., Ahangarpour, A., Khorsandi, L., & Mard, S. A. (2026). Lauric acid ameliorates endocrine-metabolic alterations in letrozole-induced polycystic ovary syndrome in female mice. Heliyon, 12(15), Article e45556. https://doi.org/10.1016/j.heliyon.2026.e45556

Image Credits: AI Generated

DOI: Not provided

Keywords: PCOS, lauric acid, coconut oil, Sirt1, AMPK, insulin resistance, letrozole, hyperandrogenism, adiponectin, PPAR gamma, oxidative stress, mouse model

Polycystic ovary syndrome, or PCOS, is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular or absent ovulation, elevated androgen levels, and polycystic ovarian morphology on ultrasound. Because anovulation is the primary barrier to conception for many of these patients, the first-line treatment is typically oral medication that nudges the ovary to release an egg. Letrozole, an aromatase inhibitor originally developed for breast cancer, and clomiphene citrate, a selective estrogen receptor modulator used for decades, are the two workhorses of this approach. When ovulation is successfully induced, couples are advised to time intercourse to the fertile window, avoiding the cost and complexity of intrauterine insemination or in vitro fertilization, at least initially.

What has been missing from clinical guidance is a well-defined stopping point. International guidelines recommend ovulation induction as first-line therapy for anovulatory PCOS, but they offer limited evidence on how many cycles a patient should complete before the therapy is deemed exhausted. Continuing too long exposes women to repeated monitoring, medication, and emotional strain with diminishing returns; stopping too early may abandon a therapy that would eventually have worked. The Chinese team, led by Yuanlin Ma and corresponding author Qingyun Mai, set out to quantify that inflection point using cumulative live birth rate, the metric that fertility specialists regard as the most meaningful measure of treatment success because it counts the outcome patients actually care about: taking home a baby.

The study was designed as a prospective cohort investigation conducted between August 1, 2020, and June 30, 2023. Crucially, the researchers restricted enrollment to women whose ovaries had already demonstrated sensitivity to letrozole or clomiphene citrate, confirmed through hospital-based monitoring during the first treatment cycle. This design choice matters scientifically: rather than asking whether the drugs work in general, the investigators isolated the question of how many cycles a confirmed responder should continue. After that first monitored cycle, subsequent cycles were managed with home ovulation monitoring, a pragmatic real-world approach that reflects how most patients actually experience treatment outside of specialized research protocols.

The headline numbers tell a story of steady but finite returns. Of the 655 women enrolled, 306 achieved 372 pregnancies, of which 257 progressed to clinical pregnancy and 206 ended in live birth. Expressed as cumulative rates over the whole cohort, 46.72 percent of women achieved pregnancy, 39.24 percent achieved a clinical pregnancy, and 31.45 percent delivered at least one live baby. When the researchers plotted cumulative live birth rate against cycle number, the curve climbed briskly through the early cycles and then flattened decisively after the eighth cycle. In other words, the vast majority of the eventual success was captured within roughly a year and a half of attempted cycles, and cycles nine and beyond contributed almost nothing to the total.

The technical logic behind a cumulative live birth curve is worth unpacking, because it explains why this kind of analysis is so useful. Each cycle carries a per-cycle probability of success, and the cumulative rate aggregates those probabilities across successive attempts, accounting for the fact that women who conceive early drop out of the denominator of those still trying. A plateau in the cumulative curve signals that the residual per-cycle success rate among women still attempting has fallen so low that further cycles barely move the total. This is the same statistical framework used to counsel patients about in vitro fertilization, where cumulative live birth curves typically plateau after a certain number of egg retrieval attempts. Applying it to oral ovulation induction gives clinicians an evidence-based benchmark for a therapy that has long been guided by convention rather than data.

Two secondary findings from the study may prove just as consequential as the headline plateau. First, the researchers found that weight reduction was associated with a substantial boost in the maximal cumulative live birth rate, lifting it from 28.00 percent in the cohort overall to 39.02 percent among patients who lost weight. This aligns with a deep body of evidence that even modest weight loss in overweight women with PCOS can restore ovulatory function, improve insulin sensitivity, and enhance endometrial receptivity. The finding underscores that lifestyle intervention is not merely an adjunct to pharmaceutical treatment but can meaningfully amplify its yield, potentially changing the calculus of how many cycles are worth pursuing.

Second, metformin use was associated with reaching the cumulative live birth plateau earlier. Metformin, an insulin-sensitizing agent widely prescribed in PCOS, is thought to improve ovulatory function by addressing the hyperinsulinemia that drives many of the syndrome’s reproductive disturbances. If patients on metformin achieve their maximal cumulative benefit in fewer cycles, that has practical implications for treatment planning: it suggests the drug may accelerate the path to success among responders, allowing couples to reach either a live birth or a decision to escalate to assisted reproduction sooner. The researchers also stratified their analyses by PCOS phenotype, comparing patients with the classic hyperandrogenic presentation against those with ovulatory dysfunction and polycystic morphology without elevated androgens, acknowledging that PCOS is not a single entity but a spectrum.

The study’s strengths lie in its size, its prospective design, and its focus on a well-defined, clinically relevant population of drug-sensitive patients, all tracked through more than two and a half thousand monitored cycles. Its limitations are those inherent to a single-center observational cohort: the findings may not generalize to women who do not respond to first-line oral agents, to centers with different monitoring practices, or to populations with different baseline characteristics. The authors also note that the analysis was conducted on an intention-to-treat basis, which preserves real-world validity but cannot fully disentangle why some women discontinued treatment early. As with any cohort study, the associations with weight loss and metformin reflect patterns in the data rather than the results of randomized manipulation.

Even with those caveats, the practical message is strikingly clear for patients and clinicians navigating the early stages of fertility care. For women with PCOS who ovulate on letrozole or clomiphene citrate, eight cycles of ovulation induction with timed intercourse appear sufficient to capture the maximal cumulative live birth rate that this therapy can deliver, with weight loss and metformin offering avenues to improve the odds within that window. Couples who have not achieved a live birth by that point now have data-driven grounds to discuss escalation to intrauterine insemination or in vitro fertilization rather than continuing indefinitely down the same path. In a field where treatment decisions have often rested on tradition and intuition, a concrete, quantified stopping rule is a rare and welcome piece of clarity, and one that could spare countless patients months of futile cycles and the emotional toll that accompanies them.

Subject of Research: Optimal number of ovulation induction cycles with timed intercourse in letrozole- or clomiphene citrate-sensitive polycystic ovary syndrome

Article Title: When to stop? assessing the appropriate cycle of ovulation induction with timed intercourse in letrozole- or clomiphene citrate-sensitive polycystic ovary syndrome

Article References: Ma, Y., Liang, Q., Wen, T., Wang, C., Hu, R., Jie, H., Xu, Y., & Mai, Q. (2026). When to stop? assessing the appropriate cycle of ovulation induction with timed intercourse in letrozole- or clomiphene citrate-sensitive polycystic ovary syndrome. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02283-8

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02283-8

Keywords: polycystic ovary syndrome, ovulation induction, letrozole, clomiphene citrate, cumulative live birth rate, timed intercourse, fertility treatment, metformin, weight loss, infertility, reproductive medicine, anovulation